Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.
Mori N, Imamura M, Kawakami Y, Saneto H, Kawaoka T, Takaki S, Aikata H, Takahashi S, Chayama K; Hiroshima Liver Study Group. Mori N, et al. Among authors: takaki s. J Med Virol. 2009 Apr;81(4):640-9. doi: 10.1002/jmv.21438. J Med Virol. 2009. PMID: 19235866 Clinical Trial.
Balloon-occluded retrograde transvenous obliteration for portal-systemic encephalopathy due to superior mesenteric-caval shunt via the right gonadal vein.
Katamura Y, Aikata H, Azakami T, Kawaoka T, Uka K, Yamashina K, Takaki S, Kodama H, Cheol JS, Hiramatsu A, Imamura M, Kawakami Y, Takahashi S, Toyota N, Ito K, Chayama K. Katamura Y, et al. Among authors: takaki s. Intern Med. 2007;46(17):1479-80. doi: 10.2169/internalmedicine.46.0120. Epub 2007 Sep 3. Intern Med. 2007. PMID: 17827854 Free article. No abstract available.
Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.
Jeong S, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Jeong S, et al. Among authors: takaki s. World J Gastroenterol. 2007 Oct 21;13(39):5188-95. doi: 10.3748/wjg.v13.i39.5188. World J Gastroenterol. 2007. PMID: 17876889 Free PMC article. Clinical Trial.
Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.
Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Jeong SC, et al. Among authors: takaki s. World J Gastroenterol. 2007 Oct 28;13(40):5343-50. doi: 10.3748/wjg.v13.i40.5343. World J Gastroenterol. 2007. PMID: 17879404 Free PMC article.
Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
Uka K, Aikata H, Takaki S, Miki D, Jeong SC, Hiramatsu A, Kodama H, Shirakawa H, Kawakami Y, Takahashi S, Toyota N, Ito K, Chayama K. Uka K, et al. Among authors: takaki s. Liver Int. 2007 Nov;27(9):1209-16. doi: 10.1111/j.1478-3231.2007.01554.x. Liver Int. 2007. PMID: 17919232
333 results